Medical and health industry weekly (January 13-17)

This week, two policies and regulations were issued, among which the notice on the implementation of the second batch of centralized purchasing and use of drugs organized by the state is the key policy of this week, which was issued by five departments including the State Health Insurance Bureau on January 16 Table 1 list of policies and regulations issued from January 13 to January 17 On January 16, in order to thoroughly implement the decision-making and deployment of the CPC Central Committee and the State Council, maintain the efforts of centralized procurement and use reform, continue to expand the effectiveness of the reform, and continue to explore and establish a standardized and normalized centralized procurement and use system of drugs, five departments including the state health insurance bureau issued the notice on carrying out the second batch of centralized procurement and use of drugs organized by the state (the following brief) Notice) The notice puts forward six requirements One is to form an alliance to summarize the demand for centralized purchase and use of drugs The other is to clarify the scope of centralized purchase and use of drugs The third is to improve the rules of centralized purchase The fourth is to adhere to the working mechanism of national organization, Alliance purchase and platform operation The fifth is to adhere to the policy and measures of volume purchase The sixth is to strengthen organizational guarantee The circular requires all localities and departments to improve their political positions, improve the leadership system, strengthen the implementation of responsibilities, establish a working mechanism, carefully organize the implementation, strengthen the publicity and guidance of reform, and strengthen risk prevention A total of 199 drug registration applications (excluding reexamination) were accepted this week According to the classification of drugs, the largest number of chemical drug registration applications was 166, accounting for 83%; biological products and traditional Chinese medicine registration applications accounted for 11% and 6%, respectively According to the classification of registration application types, 116 cases are supplementary applications, accounting for 58%; the acceptance of generic drugs accounts for 13%; the acceptance of new drugs accounts for 12%; the acceptance of imported drugs accounts for 5%; the acceptance of import re registration accounts for 2% and the acceptance of others accounts for 10% Figure 1 drug categories accepted for registration and declaration in China this week Figure 2 types of drug registration and declaration accepted nationwide this week Jiangsu Hengrui Pharmaceutical Co., Ltd., the company with the largest number of registered and applied drugs this week, has received up to 8 cases, followed by Xiehe fermentation Qilin (China) Pharmaceutical Co., Ltd., Hainan Lingkang Pharmaceutical Co., Ltd and Chengdu Yuandong biopharmaceutical Co., Ltd., all receiving up to 6 cases Figure 3 the number of drug registrations declared by enterprises in China this week top 10 In terms of consistency evaluation, there are 38 application numbers in total this week, mainly involving 27 drug categories, including amoxicillin granules, Azithromycin Capsules, aspirin enteric coated tablets, tranexamic acid injection, Piracetam Tablets, allopurinol tablets, doxofylline injection, fluconazole capsules, compound amino acid (15) dipeptide (2) injection, compound liquorice tablets, mannitol injection, etc., including Hainan Hailing The consistency evaluation application numbers of Chemical Pharmaceutical Co., Ltd and Chengdu Yuandong biopharmaceutical Co., Ltd reached 4 Table 2 list of application No for conformity assessment from January 13 to January 17 This week, there was no consistency evaluation of enterprises Domestic investment and financing events were not monitored this week In terms of overseas investment and financing market, there were 8 major investment and financing events in the field of medicine and health this week, with a total amount of US $250 million disclosed The investment targets are inframmatix, Treadwell, cardiologs, etc., mainly involving tumor, molecular diagnosis, biomedicine, sequencing and other fields Table 3 overseas investment and financing events from January 13 to January 17